Morepen Laboratories Limited — Important, 11-11-2024: General Updates

Morepen Laboratories Limited announces significant growth in Q2 FY25, with a 4% increase in revenue and notable improvements in margins, reflected by a 33% rise in EBITDA and a 64% increase in profit after tax. The company completed a QIP, raising ₹200 crore for expansion in medical devices and APIs. Focus remains on high-value markets and production capacity enhancements. The half-year figures also showed robust growth, highlighting a successful year-to-date performance.